Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Jeffrey Casberg, M.S., RPh had to say:
“There will be increased trend toward transparency in the pharmacy benefit management industry, but the net result will
likely be little or no savings to employers or government payers. Negotiated Medicare drug prices under the Inflation Reduction Act don’t go into effect until 2026. Even so, the prospect of negotiated prices will start to affect Medicare and commercial payers’ formulary management in 2024. This will be the second year that Humira (adalimumab) biosimilars will be on the market. Compared to some high year two expectations, uptake will be lower than even modest prediction.
With Wegovy (semaglutide) and Zepbound (tirzepatide) approved by the FDA and on the market, payers will be working to tighten glucagon-like peptide 1 (GLP-1) inhibitor coverage criteria in 2024 as utilization continues to ramp up. We’re also going to see increased pressure on federal and state payers to cover weight loss drugs.
The drug shortages have been a problem for several years, especially in the hospital space, and they will continue next year. It is a problem with many different causes. None of them yield to easy answers and they won’t be solved in 2024.”
Price Transparency Reveals Multiple Dimensions of Healthcare Inequities Beyond Just Patients
October 23rd 2024Pricing data shows that doctors serving these communities facing economic challenges are paid less by insurers, effectively penalizing doctors for working in areas where people most need their care.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
Patient Advocacy Groups and Caretaker Diversity in Metastatic Breast Cancer Research
October 22nd 2024Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients.
Read More